Phathom Pharmaceuticals, Inc. current report, 20 May 2021

Abrir documento

Phathom Pharmaceuticals, Inc. — Form 8-K Summary

Business Context and Reporting Period

Phathom Pharmaceuticals, Inc. filed a current report under Items 5.02 and 5.07. The filing is dated May 20, 2021, while it reports actions approved on May 20, a stockholders’ meeting held on May 21, and was signed on May 25, 2021. The company is a Delaware corporation whose common stock trades on Nasdaq under the symbol PHAT.

Financial and Operating Metrics

The filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, operating expense, or other financial performance metrics.

  • Effective July 1, 2021, annual base salaries were increased to $600,000 for President and Chief Executive Officer Terrie Curran, $500,000 for Chief Operating Officer Azmi Nabulsi, M.D., M.P.H., and $438,000 for Chief Financial Officer Todd Branning.
  • The Board increased the annual meeting stock option grant for non-employee directors from 10,000 to 12,500 shares.

Material Changes Versus the Prior Comparable Period

The filing does not present a prior-period financial comparison. Reported changes are limited to executive compensation and non-employee director equity compensation.

Governance, Outlook, Risks, and Unusual Items

  • Stockholders elected Michael F. Cola and Asit Parikh, M.D., Ph.D. as Class II directors for terms expiring at the 2024 annual meeting or until successors are elected and qualified.
  • Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal 2021.
  • Director election results included broker non-votes of 2,715,714 for each nominee. Michael F. Cola received 22,021,503 votes for and 2,825,681 withheld; Asit Parikh received 21,554,980 votes for and 3,292,204 withheld.
  • The auditor ratification received 27,548,364 votes for, zero against, and 14,534 abstentions.
  • The filing provides no financial guidance, business outlook, contingency disclosure, or material risk update.

Investor Verification Items

  1. Verify the effective date and amounts of the executive salary increases.
  2. Review the related proxy statement and equity compensation disclosures for the increased non-employee director option grant.
  3. Confirm the director election results, term lengths, and broker non-votes.
  4. Confirm Ernst & Young LLP’s appointment for fiscal 2021.
  5. Consult the company’s periodic financial filings for revenue, cash position, liquidity, debt, operating losses, and financing needs, which are not included in this 8-K.